Core Insights - The company focuses on two core businesses: biomass resource regeneration and synthetic biological manufacturing [1] - The domestic competitors are distributed across corresponding niche fields, indicating a competitive landscape [1] - The company possesses differentiated competitive advantages in both fields and plans to strengthen technological innovation and project implementation to consolidate its position in niche markets [1]

Core Viewpoint - Longkun Technology (301305.SZ) reported strong financial performance for Q3 2025, with significant year-on-year growth in both revenue and net profit, driven primarily by the sustainable aviation fuel (SAF) market and rising prices of used cooking oil (UCO) [1][2][3] Financial Performance - For the first three quarters of 2025, Longkun Technology achieved a revenue of 1.39 billion yuan, a year-on-year increase of 0.2%, and a net profit attributable to shareholders of 250 million yuan, up 28.9% [1] - In Q3 2025, the company reported a revenue of 530 million yuan, reflecting an 8.3% year-on-year growth, and a net profit of 100 million yuan, which is a 39.6% increase compared to the same period last year [1] - The company's Q3 performance set historical highs for both quarterly and year-to-date results, significantly exceeding market expectations [1] Market Dynamics - The demand for SAF has surged due to regulatory policies mandating blending of aviation fuel in various countries, leading to increased competition for raw materials [2] - As of October 2025, the price of UCO abroad reached $1,116 per ton, a 12% increase since the beginning of the year, while domestic prices for waste cooking oil have risen to 6,850 yuan per ton, a 19% increase [2] Business Operations - Longkun Technology is a key player in the UCO market, leveraging its comprehensive waste oil collection and processing system to enhance profitability [3][4] - Approximately 55% of the company's revenue and 52% of its gross profit in the first half of 2025 came from bioenergy products, with rising UCO prices positively impacting profit margins [3] - The company operates 35 biomass resource regeneration projects, with 21 already in operation, and holds the leading market share in major cities like Beijing, Shenzhen, and Guangzhou [4] Strategic Initiatives - In 2023, Longkun Technology initiated a significant strategic transformation towards biotechnology, focusing on synthetic biological manufacturing [5] - The company’s subsidiary, Longjian Biotechnology, has received approval for its human milk oligosaccharides (HMOs) product, positioning it as the first domestic enterprise to achieve this milestone [5] - The HMO project is expected to scale production by 2026, tapping into the growing market for high-value nutritional components as consumer awareness of "precision nutrition" increases [5]

Core Viewpoint - The company reported a significant increase in net profit for Q3 2025, driven by strong demand and rising prices for its core product, waste cooking oil, which is a key raw material for sustainable aviation fuel (SAF) [2][3] Financial Performance - For the first three quarters of 2025, the company achieved operating revenue of 1.386 billion yuan, a slight increase of 0.17% year-on-year; net profit attributable to shareholders was 249 million yuan, representing a year-on-year growth of 28.89% [1] - In Q3 alone, the net profit increased by 39.55% year-on-year, indicating a strong quarterly performance [2] - The company's operating cash flow remained robust, with a net amount of 367 million yuan for the first three quarters, up 5.80% year-on-year [2] Business Development - The company's biomass resource regeneration business is a core driver of its performance growth, benefiting from the upcoming mandatory blending ratio policy for SAF in Europe, which is expected to boost demand and prices for used cooking oil (UCO) [3] - The company has secured long-term stable rights for kitchen waste treatment through a BOT model, ensuring a low-cost supply of raw materials [3] - Currently, the company operates 35 biomass resource regeneration centers, with 21 already in operation, including five projects with a daily processing capacity of over 1,000 tons [3] Synthetic Biology Initiatives - The company is actively expanding into synthetic biology, with its human milk oligosaccharides (HMO) product entering the trial production phase [4] - The first phase of the HMO project involves 260 tons and is progressing smoothly, with key products receiving necessary approvals and certifications for market access [4] - The company has established connections with major target customers and is entering the qualification process for leading dairy enterprises, which is expected to generate revenue and profit starting next year [4] Revenue Forecast - The company is projected to achieve operating revenues of 1.901 billion, 2.363 billion, and 2.750 billion yuan for 2025, 2026, and 2027, respectively, with year-on-year growth rates of 6.15%, 24.30%, and 16.38% [4] - Net profit attributable to shareholders is expected to be 300 million, 381 million, and 444 million yuan for the same years, with growth rates of 39.40%, 26.83%, and 16.48% [4] - Based on the closing price on October 24, 2025, the corresponding price-to-earnings ratios (PE) are projected to be 16.75, 13.20, and 11.34, with earnings per share (EPS) of 1.25, 1.58, and 1.84 yuan [4]

Core Insights - The stock price of Langkun Technology closed at 20.63 yuan on August 26, 2025, down 0.24% from the previous trading day, with a trading volume of 1.91 billion yuan [1] - The company reported a net profit attributable to shareholders of 147 million yuan for the first half of 2025, representing a year-on-year increase of 22.36%, and plans to distribute a cash dividend of 2 yuan for every 10 shares [1] - Langkun Technology focuses on the development of its core business areas, including biomass resource regeneration and synthetic biological manufacturing, aiming to create sustainable returns for shareholders through business structure optimization and operational efficiency improvements [1] Financial Performance - The net cash flow from operating activities for the first half of 2025 was 201 million yuan, indicating a stable financial position [1] - The company's asset-liability structure remains robust, supporting its ongoing business operations and growth strategies [1] Market Activity - On August 26, there was a net outflow of 791,000 yuan from major funds, although over the past five days, there has been an overall net inflow of 27.42 million yuan [1]

Core Viewpoint - Longkun Technology reported a stable performance in its 2024 annual report, with total revenue of 1.791 billion yuan, a year-on-year increase of 2.18%, and a net profit attributable to shareholders of 216 million yuan, up 20.51% year-on-year. However, the bioenergy segment faced challenges due to an EU anti-dumping investigation, resulting in a 19.41% decline in revenue from this segment. The company is focusing on technological innovation and market expansion to mitigate these challenges and is accelerating its layout in synthetic biology manufacturing to capture a larger market share in the green economy and health industry [1][4][7]. Group 1: Biomass Resource Recycling Business - Longkun Technology has secured multiple significant projects in the biomass resource recycling sector, including a 25.5023 million yuan project in Beijing and a 1.654 billion yuan project in Tongzhou District, which has a processing capacity of 2,100 tons per day and a concession period of 40 years [4]. - Despite the success in project bidding, the bioenergy business has been impacted by the EU's anti-dumping investigation, which imposed a temporary anti-dumping tax of 23.7%, leading to a 19.41% decline in bioenergy revenue [4][6]. - The management indicated that the profit from the biodiesel business primarily comes from self-produced low-cost raw oil, suggesting that market changes have a limited impact on overall operations [4]. Group 2: Synthetic Biology Manufacturing Business - Longkun Technology is actively developing the human milk oligosaccharides (HMOs) sector, collaborating with institutions like the Hefei Institute of Physical Science to advance products such as LNT and LNnT [5][6]. - The company has made significant progress in product certification and market access, with LNnT receiving approval as a new food additive from the National Health Commission and 2'-FL obtaining Self-GRAS certification from the FDA [6][7]. - The establishment of a 1,000-ton HMO production base is underway, with the first phase expected to begin trial production in the first half of 2025 [6]. Group 3: Profit Model - Longkun Technology's profit model is diversified, comprising biomass resource recycling and synthetic biology manufacturing. The company utilizes BOT and BOO models to charge waste treatment fees and sell biodiesel and green electricity [7]. - In 2024, engineering construction revenue surged by 137.82% to 418 million yuan, while operational service revenue increased by 8.57% to 581 million yuan, indicating stable growth despite the decline in bioenergy revenue [7]. - The synthetic biology manufacturing segment is expected to become a new profit growth point as products gain market access, contributing to a 32.07% year-on-year increase in non-net profit [7].